Quick Takeaways:
- Enovis has launched CT-RevitL, the latest veterinary photobiomodulation (PBM) laser therapy system from its Companion Animal Health business in the US.
- Designed to enhance clinical performance, mobility, and ease of use, the system leverages the new COMPASS intelligent treatment guidance technology to deliver precise, calibrated dosing, helping veterinary teams reduce treatment variability and integrate high-powered laser therapy more efficiently into routine practice.
- Beyond clinical benefits, CT-RevitL is designed to support veterinary practice growth by enabling broader treatment offerings, standardized care protocols, and recurring non-drug therapy services. The system became commercially available across the US on July 13, 2026, with international rollout planned in later phases. The launch is accompanied by a comprehensive clinical education program and ongoing support from Companion Animal Health’s veterinary specialists.
Why It Matters?
CT-RevitL positions Enovis’s Companion Animal Health business to deepen its role in technology-enabled, non-drug pain and mobility management, giving clinics a more standardized, high-powered PBM platform that can turn laser therapy into a recurring, protocol-driven service line rather than an ad‑hoc modality.
Source: Globenewswire
